BCMA-targeted single-domain antibody as well as related material and application thereof

By developing single-domain antibodies targeting BCMA combined with radionuclides, probe molecules are formed for PET/CT imaging and treatment, the sensitivity and accuracy of BCMA detection and treatment in the prior art are solved, and efficient and accurate BCMA detection and treatment effects are achieved.

CN120329445AActive Publication Date: 2025-07-18TIANJIN ANTICO PHARMACEUTICAL CO LTD
6 Cites 0 Cited by

Patent Information

Application Number
CN202510827607.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-06-20
Publication Date
2025-07-18
Estimated Expiration
2045-06-20

AI Technical Summary

Technical Problem

It is difficult for the prior art to achieve sensitive and efficient detection and precise targeted treatment of BCMA. Traditional antibodies are unstable in narrow pH and temperature ranges, and new therapies such as CAR-T cell therapy and antibody drug conjugates have toxic reactions and off-target effects.

Method used

Developed single-domain antibodies targeting BCMA, including CDR1, CDR2 and CDR3 amino acid sequences that specifically bind BCMA, bind radionuclides for nuclide labeling, and form probe molecules for PET/CT imaging and treatment.

Benefits of technology

It realizes efficient and accurate detection and treatment of BCMA, reduces non-specific uptake of normal tissues, improves imaging quality, and is suitable for the diagnosis and efficacy prediction of BCMA-related tumors.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a single-domain antibody targeting BCMA as well as a related material and application thereof, and belongs to the technical field of biological medicines. The technical problem to be solved by the invention is how to realize sensitive and efficient detection and / or precise targeted therapy of BCMA. In order to solve the technical problem, the invention provides a single-domain antibody of which the amino acid sequences of CDR1, CDR2 and CDR3 are respectively shown as 28th to 35th, 49th to 60th and 97th to 112th sites of SEQ ID NO: 1. The single-domain antibody has high affinity to BCMA protein, and can specifically recognize and target BCMA positive cells. By combining with radionuclide, an anti-cancer preparation or a contrast agent, the single-domain antibody can be further developed into a targeted imaging agent, an immunotherapy drug or a single-domain antibody coupling drug for multiple myeloma, and a new strategy and thought are provided for early diagnosis, immune monitoring and targeted therapy of tumors.
Need to check novelty before this filing date? Find Prior Art